Synthesis of nanostructured mesoporous silica-coated magnetic nuclei with polyelectrolyte layers for tetracycline hydrochloride control release

Enhanced Inhibition of Drug-Resistant Escherichia coli by Tetracycline Hydrochloride-Loaded Multipore Mesoporous Silica Nanoparticles

Drug-resistant bacterial infections exhibit a major threat to public health. Thus, exploring a novel antibacterial with efficient inhibition is urgently needed. Herein, this paper describes three types of MSNs (MSNs-FC2-R1, MSNs-FC2-R0.75, MSNs-FC2-R0.5) with controllable pore size (4–6 nm) and particle size (30–90 nm) that were successfully prepared. The MSNs were loaded with tetracycline hydrochloride (TCH) for effective inhibition of Escherichia coli (ATCC25922) and TCH-resistant Escherichia coli (MQ776). Results showed that the loading capacity of TCH in three types of MSNs was as high as over 500 mg/g, and the cumulative release was less than 33% in 60 h. The inhibitory rate of MSNs-FC2-R0.5 loaded with TCH against E. coli and drug-resistant E. coli reached 99.9% and 92.9% at the concentration of MIC, respectively, compared with the other two types of MSNs or free TCH. Modified MSNs in our study showed a great application for long-term bacterial growth inhibition.

Polysaccharide/mesoporous silica nanoparticle-based drug delivery systems: A review

Mesoporous silica nanoparticles (MSNs) have been well-researched in the design and fabrication of advanced drug delivery systems (DDSs) due to their advantages such as good biocompatibility, large specific surface area and pore volume for drug loading, easily surface modification, adjusted size and good thermal/chemical stability. For MSN-based DDSs, gate materials are also necessary. And natural polysaccharides, one kind of the most abundant natural resource, have been widely applied as the "gatekeepers" in MSN-based DDSs. Polysaccharides are cheap and rich in sources with good biocompatibility, and some of them have important biological functions. In this review article, polysaccharides including chitosan, hyaluronic acid, sodium alginate and dextran, et al. are briefly introduced. And the preparation processes and properties such as controlled drug release, cancer targeting and disease diagnosis of functional polysaccharide/MSN-based DDSs are discussed.

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

Cancer treatment and therapy have made significant leaps and bounds in these past decades. However, there are still cases where surgical removal is impossible, metastases are challenging, and chemotherapy and radiotherapy pose severe side effects. Therefore, a need to find more effective and specific treatments still exists. One way is through the utilization of drug delivery agents (DDA) based on nanomaterials. In 2001, mesoporous silica nanoparticles (MSNs) were first used as DDA and have gained considerable attention in this field. The popularity of MSNs is due to their unique properties such as tunable particle and pore size, high surface area and pore volume, easy functionalization and surface modification, high stability and their capability to efficiently entrap cargo molecules. This review describes the latest advancement of MSNs as DDA for cancer treatment. We focus on the fabrication of MSNs, the challenges in DDA development and how MSNs address the problems through the development of smart DDA using MSNs. Besides that, MSNs have also been applied as a multifunctional DDA where they can serve in both the diagnostic and treatment of cancer. Overall, we argue MSNs provide a bright future for both the diagnosis and treatment of cancer.